Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
291 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dyslipidemia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 22, 18, 13, 4, 46 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 5 molecules, respectively. Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Dyslipidemia - Overview 7 Dyslipidemia - Therapeutics Development 8 Dyslipidemia - Therapeutics Assessment 23 Dyslipidemia - Companies Involved in Therapeutics Development 35 Dyslipidemia - Drug Profiles 65 Dyslipidemia - Dormant Projects 252 Dyslipidemia - Discontinued Products 261 Dyslipidemia - Product Development Milestones 265 Appendix 277
List of Tables
Number of Products under Development for Dyslipidemia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Dyslipidemia - Pipeline by Acasti Pharma Inc, H2 2017 Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2017 Dyslipidemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017 Dyslipidemia - Pipeline by Amgen Inc, H2 2017 Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2017 Dyslipidemia - Pipeline by BASF SE, H2 2017 Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H2 2017 Dyslipidemia - Pipeline by Bioleaders Corp, H2 2017 Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H2 2017 Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Cadila Healthcare Ltd, H2 2017 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H2 2017 Dyslipidemia - Pipeline by Cardax Inc, H2 2017 Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017 Dyslipidemia - Pipeline by Celon Pharma SA, H2 2017 Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2017 Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 Dyslipidemia - Pipeline by CJ HealthCare Corp, H2 2017 Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017 Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H2 2017 Dyslipidemia - Pipeline by Daewon Pharm Co Ltd, H2 2017 Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Daiichi Sankyo Company Ltd, H2 2017 Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2017 Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H2 2017 Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H2 2017 Dyslipidemia - Pipeline by Gilead Sciences Inc, H2 2017 Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2017 Dyslipidemia - Pipeline by Golden Biotechnology Corp, H2 2017 Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H2 2017 Dyslipidemia - Pipeline by Handok Inc, H2 2017 Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 Dyslipidemia - Pipeline by Huons Global Co Ltd, H2 2017 Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Innovent Biologics Inc, H2 2017 Dyslipidemia - Pipeline by InStar Technologies AS, H2 2017 Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H2 2017 Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Kowa Company Ltd, H2 2017 Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Lipicard Technologies Ltd, H2 2017 Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2017 Dyslipidemia - Pipeline by LipimetiX Development Inc, H2 2017 Dyslipidemia - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017 Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H2 2017 Dyslipidemia - Pipeline by Omeros Corp, H2 2017 Dyslipidemia - Pipeline by Pfizer Inc, H2 2017 Dyslipidemia - Pipeline by Pharmena SA, H2 2017 Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H2 2017 Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 Dyslipidemia - Pipeline by Samjin Pharm Co Ltd, H2 2017 Dyslipidemia - Pipeline by Sancilio & Company Inc, H2 2017 Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017 Dyslipidemia - Pipeline by Viking Therapeutics Inc, H2 2017 Dyslipidemia - Pipeline by Yuhan Corp, H2 2017 Dyslipidemia - Dormant Projects, H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..1), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..2), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..3), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..4), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..5), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..6), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..7), H2 2017 Dyslipidemia - Dormant Projects, H2 2017 (Contd..8), H2 2017 Dyslipidemia - Discontinued Products, H2 2017 Dyslipidemia - Discontinued Products, H2 2017 (Contd..1), H2 2017 Dyslipidemia - Discontinued Products, H2 2017 (Contd..2), H2 2017 Dyslipidemia - Discontinued Products, H2 2017 (Contd..3), H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
